- $68.75m
- $426.73m
- $490.74m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.4 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.14 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -13.94% | ||
| Return on Equity | -56.93% | ||
| Operating Margin | -19.48% | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 60.47 | 89.61 | 547.66 | 572.42 | 490.74 | 509.2 | 538.45 | 62.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Directors
- Gregory Davis NEC (68)
- Robert Leasure PRE (62)
- Beth Taylor CFO (56)
- John Beattie COO (54)
- James Harkness COO (56)
- William Pitchford CHO (67)
- Adrian Hardy EVP (51)
- Philip Downing SVP (52)
- Mark Bibi GCN (63)
- John Sagartz OTH (57)
- Michael Garrett OTH (54)
- Nigel Brown IND (57)
- Scott Cragg IND (44)
- Richard Johnson IND (76)
- R. Matthew Neff IND (66)
- Last Annual
- September 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 17th, 1975
- Public Since
- November 25th, 1997
- No. of Shareholders
- 412
- No. of Employees
- 1,977
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 33,869,269
- Address
- 2701 Kent Ave, WEST LAFAYETTE, 47906-1350
- Web
- https://www.inotiv.com/
- Phone
- +1 3174634527
- Contact
- Beth Taylor
- Auditors
- Ernst & Young LLP
Upcoming Events for NOTV
Q2 2025 Inotiv Inc Earnings Call
Q3 2025 Inotiv Inc Earnings Release
Similar to NOTV
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Inotiv share price?
As of Today at 21:19 UTC, shares in Inotiv are trading at $2.03. This share price information is delayed by 15 minutes.
How has the Inotiv share price performed this year?
Shares in Inotiv last closed at $2.03 and the price had moved by -51.2% over the past 365 days. In terms of relative price strength the Inotiv share price has underperformed the S&P500 Index by -56% over the past year.
What are the analyst and broker recommendations for Inotiv?
The overall consensus recommendation for Inotiv is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Inotiv dividend yield?
Inotiv does not currently pay a dividend.
Does Inotiv pay a dividend?
Inotiv does not currently pay a dividend.
When does Inotiv next pay dividends?
Inotiv does not currently pay a dividend.
How do I buy Inotiv shares?
To buy shares in Inotiv you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Inotiv?
As of the previous close price of $2.03, shares in Inotiv had a market capitalisation of $68.75m.
Where are Inotiv shares listed?
Here are the trading details for Inotiv:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NOTV
What kind of share is Inotiv?
Based on an overall assessment of its quality, value and momentum Inotiv is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Inotiv share price forecast for 2025?
The analyst consensus target price for shares in Inotiv is $5.50. That is 170.94% above the last closing price of $2.03.
Analysts covering Inotiv currently have a consensus Earnings Per Share (EPS) forecast of -$2.44 for the next financial year.
Find out moreWhat is the trend in the Inotiv share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inotiv. Over the past six months, its share price has outperformed the S&P500 Index by +14.57%.
As of the last closing price of $2.03, shares in Inotiv were trading -25.77% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Inotiv PE Ratio?
The Inotiv PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Inotiv?
Inotiv's management team is headed by:
- Gregory Davis - NEC
- Robert Leasure - PRE
- Beth Taylor - CFO
- John Beattie - COO
- James Harkness - COO
- William Pitchford - CHO
- Adrian Hardy - EVP
- Philip Downing - SVP
- Mark Bibi - GCN
- John Sagartz - OTH
- Michael Garrett - OTH
- Nigel Brown - IND
- Scott Cragg - IND
- Richard Johnson - IND
- R. Matthew Neff - IND